 |
27 Diseases |  |
27 Trials |
|
27 Trials |  |
3795 News |  |
| «12...1516171819202122232425...4546» |
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] The impact of previous disease-modifying treatment for HSCT outcome and the risk of new disease activity in MS (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2513;
The treatment outcome after HSCT in MS differed according to the previously employed DMT. HSCT was safe and effective after induction therapy.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Seroconversion following vaccination against SARS-CoV-2 in people with MS: impact of disease modifying therapy (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2510;
DMT, vaccine type and gender have differential impacts on IgG response to vaccination, both in terms of seroconversion and antibody titre. The impact of these factors on susceptibility to clinical infection and longer term protection remain to be determined.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Seroconversion following vaccination against SARS-CoV-2 in people with MS: impact of disease modifying therapy (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2509;
DMT, vaccine type and gender have differential impacts on IgG response to vaccination, both in terms of seroconversion and antibody titre. The impact of these factors on susceptibility to clinical infection and longer term protection remain to be determined.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Serological response to SARS-CoV-2 vaccination in multiple sclerosis patient in a real-life experience (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2494;
Anti-CD20 therapies and Fingolimod seem to condition a lower humoral response to vaccines against SARS-CoV-2. Vaccination prior initiation of these DMTs medication administration would be recommendable whenever possible.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Serological response to SARS-CoV-2 vaccination in multiple sclerosis patient in a real-life experience (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2493;
Anti-CD20 therapies and Fingolimod seem to condition a lower humoral response to vaccines against SARS-CoV-2. Vaccination prior initiation of these DMTs medication administration would be recommendable whenever possible.
- [VIRTUAL] Humoral immune response to COVID-19 mRNA (BNT162b2-Pfizer) vaccine in patients with multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2490;
Following vaccination, IgG levels declined over time, while appeared to be stable (though lower) after COVID19 disease. Testing of cellular responses in IgG-negative patients and an update of COVID19 vaccination guidelines for MS according to therapy and patient's characteristics, seem to be warranted.
- [VIRTUAL] Humoral immune response to COVID-19 mRNA (BNT162b2-Pfizer) vaccine in patients with multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2489;
Following vaccination, IgG levels declined over time, while appeared to be stable (though lower) after COVID19 disease. Testing of cellular responses in IgG-negative patients and an update of COVID19 vaccination guidelines for MS according to therapy and patient's characteristics, seem to be warranted.
- Tysabri (natalizumab) / Biogen
[VIRTUAL] Identification of a pharmacogenetic variant in NOX3 involved in the clinical response to natalizumab (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2478;
Interestingly enough, the same variant was deemed as predictive of poor clinical response in patients treated with dimethyl-fumarate. This is a first attempt to analyse genetic predictors of response to treatment using a candidate gene approach, while there is an ongoing effort to replicate these findings in additional cohorts of patients and to perform whole-genome analyses on a larger set of cohorts of treated-patients in the context of the EU-funded MultipleMS grant.
- Tysabri (natalizumab) / Biogen
[VIRTUAL] Identification of a pharmacogenetic variant in NOX3 involved in the clinical response to natalizumab (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2477;
Interestingly enough, the same variant was deemed as predictive of poor clinical response in patients treated with dimethyl-fumarate. This is a first attempt to analyse genetic predictors of response to treatment using a candidate gene approach, while there is an ongoing effort to replicate these findings in additional cohorts of patients and to perform whole-genome analyses on a larger set of cohorts of treated-patients in the context of the EU-funded MultipleMS grant.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] External validation of the MSBase model of individual treatment response (Crystal Ball 1.0) (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2456;
The previously developed models show excellent external validity. This validation of the original model in a non-overlapping cohort from the ME establishes generalizability of the Crystal Ball 1.0 model and exchangeability of its observations, which are critical for its application in practice.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] External validation of the MSBase model of individual treatment response (Crystal Ball 1.0) (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2455;
The previously developed models show excellent external validity. This validation of the original model in a non-overlapping cohort from the ME establishes generalizability of the Crystal Ball 1.0 model and exchangeability of its observations, which are critical for its application in practice.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Impact of an educational program on the DMF persistence in real-life: TECFIRELIFE study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2438;
This validation of the original model in a non-overlapping cohort from the ME establishes generalizability of the Crystal Ball 1.0 model and exchangeability of its observations, which are critical for its application in practice. Objectives: The aim of the TECFIRLIFE study (TECFIder
- dimethyl fumarate / Generic mfg.
[VIRTUAL] The role of disease modifying therapies in rate and severity of COVID-19 infection in a cohort of MS and NMOSD (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2437;
The risk for No DMT cases were lower than treated ones. Any progression or relapsing in disease course didn't occur in these confirmed infected patients.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Treatment patterns in patients with multiple sclerosis: a single hospital cohort study in Sweden (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2434;
Most patients were treated with a DMT within months of diagnosis, with predominant initial use of interferons, and switching to more potent agents in later lines of therapy. Prescribing patterns are changing and expected to evolve further with earlier use of powerful agents.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] COVID-19 vaccination and humoral immune response in people with multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2427;
Some patients treated with anti-CD20 and fingolimod failed to develop a post-vaccination humoral response. Adverse events were similar to the general population.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
[VIRTUAL] Multiple sclerosis patients initiating ofatumumab in the real-world: 6 months data (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2414;
Most patients newly initiated ofatumumab had no treatment in the prior year. Understanding patient profile, prior DMT use in the real-world may help stakeholders guide treatment decisions.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Cladribine in a real world setting. The real patients (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2409;
23 patients switch from teriflunomide, 16 from dimethylfumarate, 14 from fingolimod, 22 from injectables, 1 from alemtuzumab... In the real world cladribine has proved to be effective, safe and very well tolerated.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2407;
In the real world cladribine has proved to be effective, safe and very well tolerated. Our findings suggests that dimethyl fumarate has a lower risk of discontinuation because of treatment failure among both treatment-experienced and treatment-naive patients.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Relapse during the washout period predicts time to relapse after switching to cladribine (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2400;
Washout durations shorter than two months were associated with fewer washout relapses. Prospective studies are needed to assess if washout period reduction can modify relapse outcomes when switching to cladribine.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Effectiveness of relapsing multiple sclerosis patients switching to teriflunomide following disease progression in a real-world setting (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2398;
Following switch to teriflunomide, patients demonstrated numerical reductions in mean EDSS, and most demonstrated stability or improvement in ARR, MRI lesions, and use of ambulatory aids. Long-term assessment of this cohort may aid in understanding the impact of teriflunomide on clinical outcomes in disease progressing RMS patients.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] MASTER-2 trial: cladribine tablets in patients with relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis after suboptimal response to prior infusion/oral disease-modifying therapy (interim baseline results) (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2391;
P=N/A
MASTER-2 will report real-world data on the effects of CladT3.5 after a suboptimal response to oral/infusion DMT. Baseline analysis is ongoing and results from a data cut in July 2021 will be shown in the presentation.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Early data suggests diroximel fumarate has high rates of real-world adherence and persistence (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2390;
The finding that higher persistence is seen with newer DMTs vs older DMTs should be explored in future matched comparisons. These data support DRF as a well-tolerated fumarate.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Therapeutic management of relapsing-remitting multiple sclerosis in France in the recent era (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2383;
Our results suggest that moderately effective first-line DMTs do not always allow an effective control of the disease. Therapeutic management is a key element of current MS care (when switch and to what).
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Multiple sclerosis patients treated with diroximel fumarate over 1 year in the real-world setting have high rates of persistence and adherence (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2378;
Adherence was also high in the prior DMF subgroup. The most common reason for discontinuing prior DMF was GI AEs; most of the prior DMF pts were able to remain on DRF, further supporting improved GI tolerability with DRF.
- Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Anti-Spike IgG after BNT162b2 vaccine in a group of multiple sclerosis patients from an exploratory case-control study in Italy (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2376;
In our study, most MS patients produce a serological response to BNT162b2 similar to non-MS controls; however, at-risk DMTs resulted in reduced anti-Spike levels and one ocrelizumab-treated patient did not respond. These observations should be better investigated and replicated in larger studies to support clinical decision in COVID-19 vaccine management.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Effectiveness and safety of early high-efficacy vs. escalation therapy in relapsing-remitting multiple sclerosis in Argentina (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2367;
Our study shows that EHE therapies prevent disease progression, relapses and new MRI lesions and demonstrated no increased risk of specific adverse events when compared to ES therapy. This data should be considered when selecting a specific treatment for MS patients.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2359;
Objective: To compare the clinical outcomes in patients on DMF and TFL in a real-world setting, where both drugs are licensed as a first-line disease modifying therapy (DMT) for RRMS... Analysis of real-world data showed that in RRMS, DMF treatment was associated with more favorable clinical outcomes compared to TFL.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] CSF inflammatory markers: prediction of treatment response in early relapsing remitting multiple sclerosis? (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2349;
The CSF inflammatory profile may provide additional prognostic information to both clinical and MRI variables, and is a possible candidate in predicting response to the first-line treatment. The association between the lymphoid chemokine CXCL13 and both disease activity and cortical pathology and its prognostic value has been confirmed in a homogenous cohort.
- Mayzent (siponimod) / Novartis
[VIRTUAL] Assessing the immune response to SARS-CoV-2 mRNA vaccines in patients with secondary progressive multiple sclerosis treated with siponimod (AMA-VACC clinical trial) (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2348;
Cohort 1 receives SARS-CoV-2 mRNA vaccination while continuing their current siponimod treatment, cohort 2 interrupts siponimod treatment for for the purpose of a full vaccination cycle and cohort 3 receives vaccination during continuous treatment with first-line DMTs (dimethylfumarate, glatirameracetate, interferons, teriflunomide) or no current treatment in clinical routine... This analysis will provide first data on the immune response after SARS-CoV-2 mRNA vaccination in patients with SPMS treated with siponimod and enable physicians to make an informed decision on the coordination of SARS-CoV-2 mRNA vaccination and SPMS treatment.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Assessing predictors of no-evidence of disease activity in RRMS patients initiating dimethyl fumarate in a real-world setting (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2345;
This could be useful in clinical practice to counsel patients regarding their response to DMF. Longer follow up and different cohorts’ analysis is currently ongoing.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Immunoglobulin repertoire analysis in multiple sclerosis patients reveals distinct treatment effects after initiation of dimethyl fumarate or teriflunomide therapy (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2343;
Although we observed slight differences in repertoire diversity on a subset level, no profound effect on maturation processes was detectable; additional patients are currently analyzed. Our results -at least partially- explain the relatively mild side effects regarding infections and moderate impact on vaccinations of both treatments.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Dimethyl fumarate and fingolimod utilization and costs for multiple sclerosis: a population-based study in the Campania Region of Italy (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2340;
DMF and fingolimod were used in similar populations (age, disability). While there were no differences in efficacy (i.e., treatment escalation), DMF was associated with higher adherence, lower treatment costs, lower hospital admissions’ rates and costs.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Assessing treatment response to oral drugs for multiple sclerosis in real world setting: a MAGNIMS study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2335;
We retrospectively collected data of RRMS patients who started fingolimod (FNG), teriflunomide (TNF) or dimethyl fumarate (DMF) according to the following criteria: treatment-naive or switching from injectable DMTs; at least 1 year treatment duration; brain MRI scan collected at baseline and year 1; at least 3 years of clinical follow-up... We extend the results of previous studies, by demonstrating that early relapses and MRI activity in the first year of treatment are associated with an increased risk of short-term confirmed disability worsening and relapses in patients treated with oral DMTs.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] COVID-19 infections and vaccinations in the Swiss Multiple Sclerosis Cohort study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2320;
211 pwMS (83%) had a relapsing, 25 (10%) a secondary progressive, 13 (5%) a primary progressive disease course and 4 (2%) a clinically isolated syndrome. Median disease duration was 12 years and median EDSS was 2.5.
- Tysabri (natalizumab) / Biogen
[VIRTUAL] MS patients treated with natalizumab have a positive serology response to SARS-CoV-2 S1/S2 following vaccination with two doses of mRNA COVID-19 vaccine (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2318;
Although all patient treated with natalizumab had protective vaccine-specific antibodies following two doses of mRNA COVID-19 vaccine, we found a significant negative correlation between IgG titer and time since starting natalizumab therapy. It is possible that an accumulate effect of a long period treatment with natalizumab, partly prevent entry of antigen-presenting cells such as dendritic and macrophages into the muscle and therefore the immune response to vaccine is slightly reduced.
- dimethyl fumarate / Generic mfg., fingolimod / Generic mfg.
[VIRTUAL] Persistent lymphopenia after dimethyl fumarate and fingolimod treatment (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2312;
It is possible that an accumulate effect of a long period treatment with natalizumab, partly prevent entry of antigen-presenting cells such as dendritic and macrophages into the muscle and therefore the immune response to vaccine is slightly reduced. ALC recovery after DMF or fingolimod withdrawal is usually rapid, nevertheless it may require longer time in some patients what potentially leading to delayed initiation of a new MS therapy.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Risk of cancer with disease-modifying drugs in multiple sclerosis: a new-user cohort design in the French nationwide claims database (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2293;
Results suggest a trend of increased risk of cancer in patients with MS who initiated IS compared with IIM. Longer follow-up of this patient population is warranted.
- ACT-01 / Accure Therap
[VIRTUAL] Synergistic effects of ACT-01 with dimethyl-fumarate or fingolimod for combination therapy in the EAE animal model of MS (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2283;
Longer follow-up of this patient population is warranted. ACT-01 in combination with fingolimod or DMF shows synergistic clinical efficacy in the EAE animal model of MS.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate: a longitudinal study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2269;
The ECS is dysregulated in MS patients, as shown by the lower levels of 2-AG and PEA. DMF treatment modulates the levels of at least 3 of the endocannabinoids (2-AG, OEA and PEA), and this modulation fluctuates depending on the endocannabinoid and treatment time, and it seems not to be associated with clinical response to DMF.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Comparing the impact of dose titration on gastrointestinal tolerability: diroximel fumarate versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2261;
GI AE incidence/severity were highest with DMF in Weeks 3 and 4, after the 1-week titration. This is consistent with DMF real-world experience, where some HCPs have employed extended titration schedules to improve GI tolerability.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Flushing and flushing-related adverse events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis: results from the Phase 3 EVOLVE-MS-2 Study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2243;
P3
Although in DRF-treated patients flushing occurred in fewer patients, the incidence of flushing for DRF was generally within the expected range when compared to rates reported in DMF controlled clinical trials. The clinical meaningfulness of the observed changes is uncertain and additional real-world studies are necessary.
- Mayzent (siponimod) / Novartis
[VIRTUAL] Safety and tolerability of conversion to siponimod with and without titration in patients with advancing forms of relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2242;
P3
Immediate conversion from other DMTs to siponimod had an acceptable safety and tolerability profile, with no unexpected findings. There was no evidence of a meaningful reduction in heart rate when initiating siponimod in the overall group or in subgroups stratified by prior DMTs, including subjects transitioning from fingolimod to siponimod without dose titration.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Factors associated with dimethyl fumarate induced lymphopenia in a rural multiple sclerosis cohort (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2238;
There was no evidence of a meaningful reduction in heart rate when initiating siponimod in the overall group or in subgroups stratified by prior DMTs, including subjects transitioning from fingolimod to siponimod without dose titration. Our study aims to identify factors associated with DMF induced lymphopenia, evaluate risk factors for patients and build a prediction model to provide more information for doctors to estimate patients’ benefits/risks for MS patients
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] A retrospective review of COVID spike protein antibody development following COVID-19 vaccination in MS patients on disease modifying drugs (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2235;
This study is limited in retrospective design, small un-balanced groups, and lack of longitudinal data. We cannot exclude the possibility of a more robust delayed humoral response.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Demographic features and clinical course of pediatric-onset MS patients on newer disease-modifying treatments (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2224;
POMS patients who initiated treatment between 10- <18 years with dimethyl fumarate, fingolimod, natalizumab, rituximab or ocrelizumab were included and analyzed as individual cohorts... Though limited by relatively short treatment duration with the index DMTs, our data suggest clinical and MRI benefit in a large number of POMS patients, which can be used to guide future studies in this population.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2217;
In addition, we found a superior effect of natalizumab on reducing the rate of disability worsening and improving disability. This study demonstrates the capacity of ATE and ATT MSM to evaluate the effectiveness of multiple MS therapies simultaneously.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Disease-modifying therapy effect on COVID-19 vaccine response in multiple sclerosis patients: data from two New York State Multiple Sclerosis Consortium centers (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2200;
MS patients treated with B-cell depleting medications and S1P modulators have significantly lower seroconversion after COVID-19 vaccination when compared to DMT-naïve patients and other DMT groups. Future studies should determine the risk of severe clinical outcomes in vaccinated patients with no evidence of seroconversion.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Circulating microRNAs in RRMS patients treated with dimethyl fumarate in the phase 4 TREMEND trial (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2149;
Altered expression peaked after 6 months. This may either reflect mechanisms of DMF or change in MS disease-related pathways.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] The effect of dimethyl fumarate on white matter integrity and cognitive functioning 6-18 months after initiation of treatment in patients with relapsing-remitting multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2052;
Whether this effect persists after a longer period of DMF treatment will need to be established at 18 months follow-up, which is currently being collected. This project has been funded by Biogen.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Quantitative spinal cord MRI as a biomarker of treatment response to dimethyl fumarate in MS (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2024;
There were no significant changes in quantitative SC-MRI measures in pwMS on DMF, similar to what was observed in HCs. Our findings suggest that treatment with DMF prevents MS-related microstructural change in the SC over two years, promoting the utility of quantitative SC-MRI as a biomarker of treatment response in MS.